The move was agreed with SAP co-founder Dietmar Hopp - who is an early backer and owner of a stake of more than 80% in CureVac - German Economy Minister Peter Altmaier and Hopp said in an online media briefing.
Germany will take a stake of about 23% in unlisted biotech firm CureVac by backing a 300 million euro ($337 million) capital increase to fund the company's further development of a COVID-19 vaccine.
The move was agreed with SAP co-founder Dietmar Hopp - who is an early backer and owner of a stake of more than 80% in CureVac - German Economy Minister Peter Altmaier and Hopp said in an online media briefing.
Reuters earlier reported that a state investment had been agreed.
Comments
0 comment